(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/112514 A1

(51) International Patent Classification:
A61K 31/445 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2019/062718

(22) International Filing Date:
22 November 2019 (22.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/773,367 30 November 2018 (30.11.2018) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46206-6288 (US).

(72) Inventors: **DOWLESS, Michele Suzanne**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **GONG, Xueqian**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **STANCATO, Louis Frank**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **MYERS, James B.** et al.; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title:** AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA



(I)

(57) **Abstract:** The present invention provides an inhibitor of Aurora A kinase, Formula (I) illustrated below, or pharmaceutically acceptable salt thereof, for use in treating neuroblastoma.

WO 2020/112514 A1